A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
Condition(s):Prostatic NeoplasmsLast Updated:March 27, 2024Recruiting
Include Studies Not Open or Pending
Condition(s):Prostatic NeoplasmsLast Updated:March 27, 2024Recruiting
Condition(s):Prostate CancerLast Updated:October 31, 2022Recruiting
Condition(s):Prostatic Hyperplasia; Prostate CancerLast Updated:August 21, 2023Recruiting
Condition(s):Pituitary; AgingLast Updated:August 14, 2023Recruiting
Condition(s):Prostate CancerLast Updated:July 28, 2016Not yet recruiting
Condition(s):Cancer of ProstateLast Updated:February 7, 2024Recruiting
Condition(s):Prostate Cancer; BRCA1 Mutation; BRCA2 Mutation; Prostatic Adenocarcinoma; High-Risk CancerLast Updated:January 5, 2024Recruiting
Condition(s):Central Precocious PubertyLast Updated:February 29, 2024Recruiting
Condition(s):Endometrial Neoplasm Malignant Stage ILast Updated:March 28, 2023Recruiting
Condition(s):Castration-resistant Prostate Cancer Patients With OligometastasesLast Updated:October 20, 2020Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.